Genenta Science (GNTA) News Today $3.81 +0.10 (+2.72%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 26.5% in FebruaryGenenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 2,500 shares, a drop of 26.5% from the January 31st total of 3,400 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is currently 0.2 days.March 3 at 8:26 AM | marketbeat.comShort Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Expands By 30.8%Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 3,400 shares, a growth of 30.8% from the January 15th total of 2,600 shares. Based on an average daily volume of 10,600 shares, the days-to-cover ratio is currently 0.3 days.February 17, 2025 | marketbeat.comIs Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?February 13, 2025 | msn.comGenenta Science (NASDAQ:GNTA) Shares Up 1.3% - Here's What HappenedGenenta Science (NASDAQ:GNTA) Trading 1.3% Higher - Time to Buy?February 11, 2025 | marketbeat.comGenenta Science SpA ADRFebruary 1, 2025 | investing.comTOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 28, 2025 | prnewswire.comGenenta Science (NASDAQ:GNTA) Stock Price Down 1.3% - Time to Sell?Genenta Science (NASDAQ:GNTA) Trading Down 1.3% - Should You Sell?January 18, 2025 | marketbeat.comGenenta Science (NASDAQ:GNTA) Shares Down 1.3% - Here's WhyGenenta Science (NASDAQ:GNTA) Shares Down 1.3% - What's Next?January 18, 2025 | marketbeat.comGenenta Science announces amendment to pact with AGC BiologicsJanuary 10, 2025 | finance.yahoo.comGenenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy ManufacturingJanuary 9, 2025 | globenewswire.comITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 8, 2025 | prnewswire.comGenenta Science Enhances Manufacturing Agreement with AGC BiologicsJanuary 1, 2025 | markets.businessinsider.comGenenta Science S.p.A. (NASDAQ:GNTA) Sees Large Increase in Short InterestGenenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 3,100 shares, a growth of 121.4% from the November 30th total of 1,400 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is currently 0.2 days.December 27, 2024 | marketbeat.comGenenta Science Updates ATM Sales Agreement with New AgentDecember 20, 2024 | tipranks.comGenenta Science (NASDAQ:GNTA) Stock Price Up 2.4% - Here's WhyGenenta Science (NASDAQ:GNTA) Stock Price Up 2.4% - Still a Buy?December 13, 2024 | marketbeat.comGenenta Science (NASDAQ:GNTA) Stock Price Down 4.9% - Should You Sell?Genenta Science (NASDAQ:GNTA) Trading Down 4.9% - Time to Sell?November 21, 2024 | marketbeat.comGenenta Science S.p.A. (NASDAQ:GNTA) Sees Large Growth in Short InterestGenenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 11,600 shares, an increase of 152.2% from the September 30th total of 4,600 shares. Based on an average daily trading volume, of 12,300 shares, the days-to-cover ratio is currently 0.9 days.October 26, 2024 | marketbeat.comGenenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”October 23, 2024 | globenewswire.comGenenta Science (NASDAQ:GNTA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insidersOctober 11, 2024 | finance.yahoo.comBuy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy TrialsOctober 4, 2024 | markets.businessinsider.comGenenta Science's (GNTA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Genenta Science in a report on Wednesday.October 2, 2024 | marketbeat.comGenenta Secures Approval for Innovative Trial for Metastatic Renal Cell CancerOctober 2, 2024 | globenewswire.comGenenta Science S.p.A. (GNTA): Early Investment Opportunity in Innovative BiotechSeptember 30, 2024 | finance.yahoo.comAlTi Global Inc. Acquires Shares of 200,288 Genenta Science S.p.A. (NASDAQ:GNTA)AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 200,288 shares of the company's stock, valued at approximately $621,000September 26, 2024 | marketbeat.comGenenta Science (NASDAQ:GNTA) Stock Price Up 5.4%Genenta Science (NASDAQ:GNTA) Stock Price Up 5.4%September 24, 2024 | marketbeat.comGenenta Science S.p.A. (NASDAQ:GNTA) Sees Significant Decrease in Short InterestGenenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 12,000 shares, a decline of 14.9% from the July 31st total of 14,100 shares. Based on an average daily volume of 11,400 shares, the days-to-cover ratio is presently 1.1 days.September 2, 2024 | marketbeat.comShort Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Rises By 47.1%Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 5,000 shares, an increase of 47.1% from the May 31st total of 3,400 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is presently 1.2 days.June 29, 2024 | marketbeat.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comAnalysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)May 10, 2024 | markets.businessinsider.comTrading was temporarily halted for "GNTA" at 10:05 AM with a stated reason of "LULD pause."May 9, 2024 | marketbeat.comGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderMay 6, 2024 | finance.yahoo.comGenenta Welcomes New Directors John L. Cantello, Lauren H.May 6, 2024 | globenewswire.comTrading was temporarily halted for "GNTA" at 11:04 AM with a stated reason of "LULD pause."April 24, 2024 | marketbeat.comGenenta Science SpA Sponsored ADRApril 11, 2024 | cnn.comBioVie stock plunges 43% following public offering pricingMarch 4, 2024 | msn.comTrading was temporarily halted for "GNTA" at 09:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comBuy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy PlatformFebruary 10, 2024 | markets.businessinsider.comGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsFebruary 8, 2024 | finance.yahoo.comIs Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?February 3, 2024 | finance.yahoo.comGenenta Science (NASDAQ:GNTA) Stock Price Down 7.2%Genenta Science (NASDAQ:GNTA) Trading Down 7.2%February 3, 2024 | marketbeat.comTrading was temporarily halted for "GNTA" at 11:11 AM with a stated reason of "LULD pause."November 22, 2023 | marketbeat.comIndividual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%November 14, 2023 | finance.yahoo.comGenenta Science S.p.A. (GNTA)August 18, 2023 | au.finance.yahoo.comGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsJuly 28, 2023 | finance.yahoo.comTrading was temporarily halted for "GNTA" at 12:07 PM with a stated reason of "LULD pause."July 13, 2023 | marketbeat.comHere's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn SituationJuly 8, 2023 | finance.yahoo.comGENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of GliomaJune 29, 2023 | finanznachrichten.deThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaJune 29, 2023 | finance.yahoo.comInsiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the companyMay 17, 2023 | finance.yahoo.com Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address GNTA Media Mentions By Week GNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNTA News Sentiment▼1.580.69▲Average Medical News Sentiment GNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNTA Articles This Week▼30▲GNTA Articles Average Week Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neumora Therapeutics News Today Olema Pharmaceuticals News Today Immutep News Today Design Therapeutics News Today iTeos Therapeutics News Today Aquestive Therapeutics News Today enGene News Today Heron Therapeutics News Today DiaMedica Therapeutics News Today Atea Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNTA) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
